title: Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
authors.forename: Sabine
authors.initials: S
authors.lastname: Arnolds
authors.forename: Klaus
authors.initials: K
authors.lastname: Rave
mesh_terms: D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D004357:Drug Synergism; D006442:Glycated Hemoglobin / Q000187:drug effects; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000069036:Insulin Glargine; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D013453:Sulfonylurea Compounds / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D013453:Sulfonylurea Compounds; C057619:glimepiride